Foradil is a drug owned by Novartis Pharmaceuticals Corp. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 28, 2020. Details of Foradil's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6887459 | Aerosol composition comprising formoterol |
Nov, 2020
(4 years ago) |
Expired
|
| US6488027 | Powder inhaler |
Mar, 2019
(5 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Foradil's patents.
Latest Legal Activities on Foradil's Patents
Given below is the list of recent legal activities going on the following patents of Foradil.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 03 May, 2005 | US6887459 |
| Patent Issue Date Used in PTA Calculation Critical | 03 May, 2005 | US6887459 |
| Issue Notification Mailed Critical | 13 Apr, 2005 | US6887459 |
| Dispatch to FDC | 28 Mar, 2005 | US6887459 |
| Receipt into Pubs | 28 Mar, 2005 | US6887459 |
| Application Is Considered Ready for Issue Critical | 28 Mar, 2005 | US6887459 |
| Receipt into Pubs | 17 Mar, 2005 | US6887459 |
| Mail Response to 312 Amendment (PTO-271) Critical | 02 Mar, 2005 | US6887459 |
| Response to Amendment under Rule 312 Critical | 01 Mar, 2005 | US6887459 |
| Issue Fee Payment Received Critical | 28 Jan, 2005 | US6887459 |
US patents provide insights into the exclusivity only within the United States, but Foradil is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Foradil's family patents as well as insights into ongoing legal events on those patents.
Foradil's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Foradil's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 28, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Foradil Generic API suppliers:
Formoterol Fumarate is the generic name for the brand Foradil. 8 different companies have already filed for the generic of Foradil, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Foradil's generic
Alternative Brands for Foradil
Foradil which is used for managing symptoms and improving lung function in individuals with chronic obstructive pulmonary disease., has several other brand drugs using the same active ingredient (Formoterol Fumarate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Astrazeneca |
| |||
| Astrazeneca Ab |
| |||
| Covis |
| |||
| Mylan Speclt |
| |||
| Organon Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Formoterol Fumarate, Foradil's active ingredient. Check the complete list of approved generic manufacturers for Foradil
About Foradil
Foradil is a drug owned by Novartis Pharmaceuticals Corp. It is used for managing symptoms and improving lung function in individuals with chronic obstructive pulmonary disease. Foradil uses Formoterol Fumarate as an active ingredient. Foradil was launched by Novartis in 2001.
Approval Date:
Foradil was approved by FDA for market use on 16 February, 2001.
Active Ingredient:
Foradil uses Formoterol Fumarate as the active ingredient. Check out other Drugs and Companies using Formoterol Fumarate ingredient
Treatment:
Foradil is used for managing symptoms and improving lung function in individuals with chronic obstructive pulmonary disease.
Dosage:
Foradil is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.012MG/INH **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | POWDER | Discontinued | INHALATION |